New drug for chronic women’s health conditions
A new UK-based clinical-stage company called KaNDy Therapeutics has been launched, with a view to maximising the value of a potential breakthrough medicine for the treatment of chronic debilitating women’s health conditions.
The medicine, NT-814, is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal vasomotor symptoms (PMVMS). It is believed to be able to beneficially modulate dysfunctional temperature control and reproductive hormone pathways.
KaNDy Therapeutics is expected to advance the development of NT-814 into Phase 2b for the treatment of PMVMS, while also exploring its potential in other women’s health conditions. The medication has already successfully completed a Phase 2a proof-of-concept study, which demonstrated its potential to reduce the frequency and severity of PMVMS.
“The formation of KaNDy Therapeutics enables us to maximise the potential of NT-814 in a range of debilitating women’s health conditions,” commented Iain Dukes, chairman of KaNDy Therapeutics. “We believe NT-814 is one of the few true innovations in women’s health in more than two decades and potentially represents a major breakthrough in areas of significant unmet medical need such as PMVMS.”
Professor Richard Anderson, a clinical adviser at the University of Edinburgh, said that NT-184 could bring considerable relief to women as a potential once-daily alternative to HRT, without the issues associated with hormone replacement.
Article Resources: https://www.ihmt.global/story/469